Recent advancements in multimodality treatment of gliomas

Future Oncology

Volumn 7, Issue 10, 2011, Pages 1169-1183

  Hadziahmetovic, Mersiha ^a   Shirai, Katsuyuki ^a   Chakravarti, Arnab ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

glioblastoma; glioma; particle therapy; radiotherapy; targeted therapy

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARMUSTINE; CILENGITIDE; GEFITINIB; LOMUSTINE; PROCARBAZINE; TALAMPANEL; TEMOZOLOMIDE; VINCRISTINE;

APOPTOSIS; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; DIGESTIVE SYSTEM PERFORATION; EXTERNAL BEAM RADIOTHERAPY; GLIOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROTON THERAPY; RADIATION NECROSIS; REVIEW; SEIZURE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 80054112352     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.102     Document Type: Review

References (112)

1. DN Louis, H Ohgaki, OD Wiestler et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114(2), 97-109 (2007). (Pubitemid 47103521)
2. Claus EB, PM Black. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from the SEER program, 1973-2001 Cancer 106(6), 1358-1363 (2006). (Pubitemid 43363915)
3. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74(6), 1784-1791 (1994). (Pubitemid 24301834)
4. AB Karim, D Afra, P Cornu et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research And Treatment of Cancer Study 22845 with the Medical Research Council Study BRO4: an interim analysis. Int. J. Radiat. Oncol. Biol. Phys. 52(2), 316-324 (2002). (Pubitemid 34170840)
5. van den Bent MJ, Afra D, de Witte O et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366(9490), 985-990 (2005). (Pubitemid 41323034)
6. Pignatti F, van den Bent M, Curran D et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol. 20(8), 2076-2084 (2002). (Pubitemid 34408798)
7. Shaw E, Arusell R, Scheithauer B et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/ Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J. Clin. Oncol. 20(9), 2267-2276 (2002). (Pubitemid 34441653)
8. Karim AB, Maat B, Hatlevoll R et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844 Int. J. Radiat. Oncol. Biol. Phys. 36(3), 549-556 (1996). (Pubitemid 26404297)
9. Kesari S, D Schiff, J Drappatz et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin. Cancer Res. 15(1), 330-337 (2009).
10. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J. Neurooncol. 82(3), 281-288 (2007). (Pubitemid 46614391)
11. Shaw EG, Wang M, Coons S et al. Final report of radiation therapy oncology group protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). Presented at: 2008 ASCO National Meeting. Chicago, IL, USA, 30 May-3 June 2008
12. Scanlon PW, Taylor WF. Radiotherapy of intracranial astrocytomas: analysis of 417 cases treated from 1960 through 1969 Neurosurgery 5(3), 301-308 (1979). (Pubitemid 10228254)
13. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71(8), 2585-2597 (1993). (Pubitemid 23100496)
14. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). (Pubitemid 40349501)
15. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005). (Pubitemid 40349502)
16. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5 year analysis of the EORTC-NCtrial IC. Lancet Oncol. 10(5), 459-466 (2009).
17. Clarke JL, Iwamoto FM, Sul J et al. Randomized Phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 27(23), 3861-3867 (2009).
18. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized european organisation for research and treatment of cancer Phase I trial II. J. Clin. Oncol. 24(18), 2715-2722 (2006). (Pubitemid 46630567)
19. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90(19), 1473-1479 (1998). (Pubitemid 28482012)
20. Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J. Clin. Oncol. 24(18), 2707-2714 (2006). (Pubitemid 46630566)
21. Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18(3), 636-645 (2000). (Pubitemid 30078545)
22. Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7(4), 839-845 (2001). (Pubitemid 32708719)
23. Snuderl M, Eichler AF, Ligon KL et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin. Cancer Res. 15(20), 6430-6437 (2009).
24. Vogelbaum MA, Berkey B, Peereboom D et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Neuro. Oncol. 11(2), 167-175 (2009).
25. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 9(1), 58-67 (2004). (Pubitemid 38134014)
26. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22(1), 133-142 (2004). (Pubitemid 41095125)
27. van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034 J. Clin. Oncol. 27(8), 1268-1274 (2009).
28. Bianco C, Tortora G, Bianco R et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (IRESSA). Clin. Cancer Res. 8(10), 3250-3258 (2002). (Pubitemid 35155038)
29. Chakravarti A. An update of Phase II results from RTOG 0211: a Phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. Presented at: 2006 ASCO Annual Meeting. Atlanta, GA, USA 2-6 June 2006
30. Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27(4), 579-584 (2009).
31. Peereboom DM, Shepard DR, Ahluwalia MS et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol. 98(1), 93-99 (2010).
32. Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177 J. Clin. Oncol. 26(34), 5603-5609 (2008).
33. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353(19), 2012-2024 (2005). (Pubitemid 41609094)
34. Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol. 27(34), 5743-5750 (2009).
35. Tabatabai G, Stupp R, van den Bent MJ et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 120(5), 585-592 (2010).
36. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010).
37. Ahluwalia MS, Gladson CL. Progress on antiangiogenic therapy for patients with malignant glioma. J. Oncol. 2010:689018 (2010).
38. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007). (Pubitemid 350086473)
39. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
40. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142-148 (2011).
41. Taga T, Suzuki A, Gonzalez-Gomez I et al. a v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int. J. Cancer 98(5), 690-697 (2002). (Pubitemid 34228889)
42. Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26(34), 5610-5617 (2008).
43. Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(16), 2712-2718 (2010).
44. 2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med. 8(9), 971-978 (2002). (Pubitemid 35033701)
45. Grossman SA, Ye X, Chamberlain M et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial. J. Clin. Oncol. 27(25), 4155-4161 (2009).
46. Yin D, Zhou H, Kumagai T et al. Proteasome inhibitor PS 341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24(3), 344-354 (2005). (Pubitemid 40188583)
47. Kubicek GJ, Werner-Wasik M, Machtay M et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys. 74(2), 433-439 (2009).
48. Nuutinen J, Sonninen P, Lehikoinen P et al. Radiotherapy treatment planning and long-term follow-up with [(11)c]methionine pet in patients with low-grade astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 48(1), 43-52 (2000). (Pubitemid 30488211)
49. Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother. Oncol. 96(3), 325-327 (2010).
50. Grosu AL, Weber WA, Riedel E et al. L (methyl 11c) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63(1), 64-74 (2005). (Pubitemid 41583543)
51. Astner ST, Shi K, Vaupel P, Molls M. Imaging of tumor physiology: impacts on clinical radiation oncology. Exp. Oncol. 32(3), 149-152 (2010).
52. Bloom HJ. Combined modality therapy for intracranial tumors. Cancer 35(1), 111-120 (1975).
53. Hermanto U, Frija EK, Lii MJ, Chang EL, Mahajan A, Woo SY. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain? Int. J. Radiat. Oncol. Biol. Phys. 67(4), 1135-1144 (2007).
54. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 56(1), 83-88 (2003). (Pubitemid 36403679)
55. D'Souza WD, Rosen II. Nontumor integral dose variation in conventional radiotherapy treatment planning. Med. Phys. 30(8), 2065-2071 (2003). (Pubitemid 37022013)
56. Fogh SE, Andrews DW, Glass J et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J. Clin. Oncol. 28(18), 3048-3053 (2010).
57. Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D. Reirradiation of recurrent who grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). Strahlenther. Onkol. 181(12), 768-773 (2005). (Pubitemid 41813702)
58. Combs SE, Bischof M, Welzel T et al. Radiochemotherapy with temozolomide as reirradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J. Neurooncol. 89(2), 205-210 (2008).
59. Cuneo KC, Vredenburgh JJ, Sampson JH et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. doi:101016/j. ijrobp.201012074 (2011) (Epub ahead of print).
60. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J. Clin. Oncol. 25(8), 953-964 (2007). (Pubitemid 350002861)
61. Paganetti H, Niemierko A, Ancukiewicz M et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int. J. Radiat. Oncol. Biol. Phys. 53(2), 407-421 (2002). (Pubitemid 34522107)
62. Ando K, Koike S, Ohira C et al. Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int. J. Radiat. Biol. 75(4), 505-512 (1999). (Pubitemid 29191549)
63. Nakano T, Suzuki Y, Ohno T et al. Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin. Cancer Res. 12(7 Pt 1), 2185-2190 (2006).
64. Brada M, Pijls-Johannesma M, De Ruysscher D. Current clinical evidence for proton therapy. Cancer J. 15(4), 319-324 (2009).
65. Fitzek MM, Thornton AF, Rabinov JD et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a Phase II prospective trial. J. Neurosurg. 91(2), 251-260 (1999).
66. Mizumoto M, Tsuboi K, Igaki H et al. Phase I/ II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 77(1), 98-105 (2010).
67. Fitzek MM, Thornton AF, Harsh GT et al. Dose-escalation with proton/photon irradiation for daumas-duport lower-grade glioma: Results of an institutional Phase I/II trial. Int. J. Radiat. Oncol. Biol. Phys. 51(1), 131-137 (2001). (Pubitemid 32758872)
68. Hug EB, Muenter MW, Archambeau JO et al. Conformal proton radiation therapy for p low-grade astrocytomas. Strahlenther. Onkol. 178(1), 10-17 (2002). (Pubitemid 34074215)
69. Iwadate Y, Mizoe J, Osaka Y, Yamaura A, Tsujii H. High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53 Int. J. Radiat. Oncol. Biol. Phys. 50(3), 803-808 (2001). (Pubitemid 32515335)
70. Mizoe JE, Tsujii H, Hasegawa A et al. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined x ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 69(2), 390-396 (2007). (Pubitemid 47380082)
71. Combs SE, Bohl J, Elsasser T et al. Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. Int. J. Radiat. Biol. 85(2), 126-137 (2009).
72. Combs SE, Kieser M, Rieken S et al. Randomized Phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the cleopatra trial. BMC Cancer 10, 478 (2010).
73. Okada T, Kamada T, Tsuji H et al. Carbon ion radiotherapy: clinical experiences at national institute of radiological science (NIRS). J. Radiat. Res. (Tokyo) 51(4), 355-364 (2010).
74. Gruber ML, Raza S, Gruber D et al. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity. J. Clin. Oncol. 27, 15 (2009) (Abstract 2017).
75. Gilbert MR, Wang M, Aldape K et al. RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J. Clin. Oncol. 27, 15 (2009) (Abstract 2011).
76. Soffietti R, Rud̀ R, Trevisan E et al. Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: a multicenter Italian study. J. Clin. Oncol. 27, 15 (2009) (Abstract 2012).
77. Raizer JJ, Grimm S, Rice L et al. A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas. J. Clin. Oncol. 27, 15 (2009) (Abstract 2044).
78. Altaha R, Almubarak M, Newton MD et al. A pilot study of fosbretabulin with bevacizumab in recurrent high-grade gliomas. J. Clin. Oncol. 28, 15 (2010) (Abstract TPS147).
79. Bogdahn U, Schneider T, Oliushine V et al. Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: Basis for phase III endpoints. J. Clin. Oncol. 27, 15 (2009) (Abstract 2037).
80. Chi AS, Gerstner ER, Eichler AF et al. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 27 (2009) (Abstract e13010).
81. Brandes AA, Stupp R, Hau P et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur. J. Cancer 46(2), 348-354 (2010).
82. Batchelor T, Eichler AF, Plotkin SR et al. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 27 (2009) (Abstract 2035).
83. Schiff D, Reardon DA, Kesari S et al. Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). J. Clin. Oncol. 28, 15 (2010) (Abstract 2011).
84. Hainsworth JD, Ervin T, Friedman E et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116(15), 3663-3669 (2010).
85. Friedman HS, Vredenburgh JJ, Desjardins A et al. A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. J. Clin. Oncol. 27, 15 (2009) (Abstract e13024).
86. Neyns B, Chaskis C, Dujardin M et al. Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. J. Clin. Oncol. 27, 15 (2009) (Abstract 2038).
87. Supko JG, Grossman SA, Peereboom DM et al. Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma. J. Clin. Oncol. 27, 15 (2009) (Abstract 2039).
88. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168-1174 (2010).
89. Butowski NA, Lamborn K, Chang S et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide and radiation therapy in patients with glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27, 15 (2009) (Abstract 2020).
90. Sarkaria JN, Galanis E, Wu W et al. NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients. J. Clin. Oncol. 27, 15 (2009) (Abstract 2019).
91. Mason WP, MacNeil M, Easaw J et al. A phase I study of temozolomide (TMZ) and RAD001 in patients (pts) with glioblastoma multiforme (GBM). J. Clin. Oncol. 27, 15 (2009) (Abstract 2036).
92. Fiveash JB, Chowdhary SA, Peereboom D. NABTT-0702: A phase II study of R-(-)- gossypol (AT-101) in recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. 27, 15 (2009) (Abstract 2010).
93. Lamar RE, Spigel DR, Burris HA et al. Phase II trial of radiation therapy/temozolomide followed by temozolomide/sorafenib in the first-line treatment of glioblastoma multiforme (GBM). J. Clin. Oncol. 27, 15 (2010) (Abstract 2018).
94. Desjardins A, Reardon DA, Gururangan S et al. Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J. Clin. Oncol. 27 (2009) (Abstract e13004).
95. Chinnaiyan P, Chowdhary S, Brem S et al. A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma. J. Clin. Oncol. 28, 15 (2010) (Abstract TPS150).
96. Blakeley JO, Ye X, Grossman SA et al. Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma. J. Clin. Oncol. 28, 15 (2010) (Abstract 2012).
97. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. J. Clin. Oncol. 27, 15 (2009) (Abstract 2045).
98. Drappatz J, Norden AD, Wong ET. Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 27, 15 (2009) (Abstract 2031).
99. Herndon J, Vredenburgh J, Reardon D et al. Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. J. Clin. Oncol. 27 (2009) (Abstract e13016).
100. Kirkpatrick JP, Vredenburgh JJ, Desjardins A et al. Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. J. Clin. Oncol. 27, (2009) (Abstract e13007).
101. Mcnicol KA, Kreisl TN, Iwamoto FM et al. Phase I/II study of vandetanib for patients with recurrent malignant gliomas. J. Clin. Oncol. 28, 15 (2010) (Abstract 2083).
102. Hasselbalch B, Lassen U, Hansen S et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro. Oncol. 12(5), 508-516 (2010).
103. Chang SM, Kuhn J, Lamborn K et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J. Clin. Oncol. 27, 15 (2009) (Abstract 2004).
104. Reardon D, Desjardins A, Vredenburgh JJ et al. Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. J. Clin. Oncol. 27, 15 (2009) (Abstract 2046).
105. Prados M, Gilbert M, Kuhn J et al. Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J. Clin. Oncol. 27, 15 (2009) (Abstract 2005).
106. Wen PY, Cloughesy T, Kuhn J et al. Phase I/ II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J. Clin. Oncol. 27, 15 (2009) (Abstract 2006).
107. De Groot JF, Prados M, Urquhart T et al. A Phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J. Clin. Oncol. 27, 15 (2009) (Abstract 2047).
108. Wen PY, Prados M, Schiff D et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J. Clin. Oncol. 28, 15 (2010) (Abstract 2006).
109. Frentzas SN, Groves MD, Barriuso J et al. Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J. Clin. Oncol. 27, 15 (2009) (Abstract 2040).
110. Fink K, Mikkelsen T, Nabors LB et al. Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study. J. Clin. Oncol. 28, 15 (2009) (Abstract 2010).
111. Drappatz J, Brenner AJ, Rosenfeld S et al. ANG1005: Results of a phase I study in patients with recurrent malignant glioma. J. Clin. Oncol. 28, 15 (2010) (Abstract 2009).
112. Benouaich-Amiel A, Mazza E, Massard C et al. Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG). J. Clin. Oncol. 28, 15 (2010) (Abstract 2087).